In:
Journal of Medical Virology, Wiley, Vol. 90, No. 2 ( 2018-02), p. 304-312
Abstract:
There are limited data regarding the real world effectiveness of direct acting antivirals (DAA) for the therapy of chronic genotype 3 hepatitis C virus (HCV) infection. All HCV genotype 3 infected patients from the German hepatitis C cohort (GECCO), which is a prospective database of nine German hepatitis C treatment centers, were included in the study. Three hundred forty‐two chronically infected HCV genotype 3 patients were analyzed (253 males [74.0%], mean age 47.3 years, 127 cirrhotic patients [37.1%] mostly with Child A cirrhosis, 113 treatment experienced patients [37.1%], 38 HCV/HIV co‐infected patients [11.1%] ). SVR12 rates in the “intention‐to‐treat” analysis were as follows: sofosbuvir/ribavirin 69.4% (75/108), sofosbuvir/peginterferon/ribavirin 80.6% (58/72), sofosbuvir/daclatasvir ± ribavirin for 12 weeks 88.3% (53/63), sofosbuvir/daclatasvir ± ribavirin for 24 weeks 79.3% (23/29), sofosbuvir/ledipasvir ± ribavirin for 12 weeks 71.4% (10/14), and sofosbuvir/ledipasvir ± ribavirin for 24 weeks 86.7% (26/30). Forty patients were lost to follow‐up, 23 patients had a relapse, 4 patients stopped treatment prematurely and 1 patient died. Female sex ( P = 0.038) and treatment with two different DAAs ( P = 0.05) were predictors for SVR12 in the multivariate analysis. In conclusion, sofosbuvir/daclatasvir ± ribavirin for 12 weeks and sofosbuvir/ledipasvir ± ribavirin for 24 weeks are effective for the treatment of HCV genotype 3 infected patients including cirrhotic, treatment‐experienced or HIV/HCV co‐infected patients.
Type of Medium:
Online Resource
ISSN:
0146-6615
,
1096-9071
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
752392-0
detail.hit.zdb_id:
1475090-9